SK287787B6 - Použitie L-karnitínu ako stabilizačného činidla proteínov - Google Patents

Použitie L-karnitínu ako stabilizačného činidla proteínov Download PDF

Info

Publication number
SK287787B6
SK287787B6 SK890-2003A SK8902003A SK287787B6 SK 287787 B6 SK287787 B6 SK 287787B6 SK 8902003 A SK8902003 A SK 8902003A SK 287787 B6 SK287787 B6 SK 287787B6
Authority
SK
Slovakia
Prior art keywords
carnitine
crystalline
lenses
proteins
protein
Prior art date
Application number
SK890-2003A
Other languages
English (en)
Slovak (sk)
Other versions
SK8902003A3 (en
Inventor
Menotti Calvani
Original Assignee
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. filed Critical Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Publication of SK8902003A3 publication Critical patent/SK8902003A3/sk
Publication of SK287787B6 publication Critical patent/SK287787B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
SK890-2003A 2000-12-15 2000-12-15 Použitie L-karnitínu ako stabilizačného činidla proteínov SK287787B6 (sk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IT2000/000520 WO2002048190A1 (en) 2000-12-15 2000-12-15 Use of l-carnitine as stabilizing agent of proteins

Publications (2)

Publication Number Publication Date
SK8902003A3 SK8902003A3 (en) 2003-12-02
SK287787B6 true SK287787B6 (sk) 2011-09-05

Family

ID=11133601

Family Applications (1)

Application Number Title Priority Date Filing Date
SK890-2003A SK287787B6 (sk) 2000-12-15 2000-12-15 Použitie L-karnitínu ako stabilizačného činidla proteínov

Country Status (15)

Country Link
US (1) US7833977B2 (pl)
EP (1) EP1341813B1 (pl)
AT (1) ATE339445T1 (pl)
AU (1) AU2001223953A1 (pl)
CA (1) CA2434911C (pl)
CY (1) CY1106235T1 (pl)
DE (1) DE60030787T2 (pl)
DK (1) DK1341813T3 (pl)
ES (1) ES2272351T3 (pl)
HU (1) HU230002B1 (pl)
MX (1) MXPA03006266A (pl)
PL (1) PL199984B1 (pl)
PT (1) PT1341813E (pl)
SK (1) SK287787B6 (pl)
WO (1) WO2002048190A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2414775A1 (en) 2000-05-03 2001-11-08 Expressive Constructs, Inc. A method and device for improving protein stability and solubility
ES2272351T3 (es) 2000-12-15 2007-05-01 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Uso de l-carnitina como agente estabilizante de proteinas.
EP1624886A2 (en) * 2003-05-12 2006-02-15 Expressive Constructs, Inc. Methods for increasing cell and tissue viability
WO2011075430A1 (en) * 2009-12-14 2011-06-23 University Of Massachusetts Methods of inhibiting cataracts and presbyopia
US20200140500A1 (en) * 2012-07-17 2020-05-07 The Regents Of The University Of Michigan High throughput methods, protein inhibitors, and uses thereof
EP2968239B1 (en) 2013-03-14 2019-04-24 The University of Massachusetts Methods of inhibiting cataracts and presbyopia
JP6794444B2 (ja) 2015-11-13 2020-12-02 ユニバーシティ オブ マサチューセッツ 白内障および老視の抑制に用いられるｐｅｇを含有する二官能性分子を含む眼科用組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1235153B (it) * 1988-11-15 1992-06-22 Sigma Tau Ind Farmaceuti Uso dell'acetil l-carnitina nel trattamento terapeutico della cataratta e composizioni farmaceutiche utili in tale trattamento
US20040058015A1 (en) * 2000-06-01 2004-03-25 Yuanjin Tao Compositions and methods for treating eye discomfort and eye disease
ES2272351T3 (es) 2000-12-15 2007-05-01 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Uso de l-carnitina como agente estabilizante de proteinas.
ITRM20010294A1 (it) * 2001-05-29 2002-11-29 Sigma Tau Ind Farmaceuti Uso della acetil l-carnetina in associazione con la biotina per il trattamento di pazienti affetti da diabete mellito di tipo ii insulino re
US6923960B2 (en) * 2001-10-03 2005-08-02 Vsl Pharmaceuticals Inc. Antioxidant combination composition and use thereof
US20050163873A1 (en) * 2004-01-14 2005-07-28 Robert Ritch Methods and formulations for treating glaucoma
ITRM20040327A1 (it) * 2004-07-01 2004-10-01 Sigma Tau Ind Farmaceuti Uso della acetil l-carnitina per la preparazione di un medicamento per il trattamento del dolore neuropatico in pazienti diabetici.
US8569366B2 (en) * 2005-04-26 2013-10-29 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Acetyl L-carnitine for prevention of painful peripheral neuropathy in patients with type 2 diabetes

Also Published As

Publication number Publication date
AU2001223953A1 (en) 2002-06-24
HUP0400737A3 (en) 2013-06-28
WO2002048190A1 (en) 2002-06-20
DE60030787D1 (de) 2006-10-26
DE60030787T2 (de) 2007-09-13
PL199984B1 (pl) 2008-11-28
SK8902003A3 (en) 2003-12-02
US7833977B2 (en) 2010-11-16
MXPA03006266A (es) 2004-06-25
HUP0400737A2 (hu) 2004-07-28
HU230002B1 (en) 2015-04-28
EP1341813A1 (en) 2003-09-10
EP1341813B1 (en) 2006-09-13
DK1341813T3 (da) 2007-01-15
CY1106235T1 (el) 2011-06-08
CA2434911C (en) 2009-12-08
PT1341813E (pt) 2007-01-31
CA2434911A1 (en) 2002-06-20
ATE339445T1 (de) 2006-10-15
PL367204A1 (pl) 2005-02-21
US20040120967A1 (en) 2004-06-24
ES2272351T3 (es) 2007-05-01

Similar Documents

Publication Publication Date Title
Trelstad et al. Isolation of two distinct collagens from chick cartilage
Kannan et al. Novel roles for α-crystallins in retinal function and disease
Currie et al. Characterization of the synthesis and accumulation of a 71-kilodalton protein induced in rat tissues after hyperthermia
KR100864380B1 (ko) 두뇌기능 향상과 뇌신경계 질환 예방 또는 치료용 펩타이드
US6472436B1 (en) Methods for protecting cells from amyloid toxicity and for inhibiting amyloid protein production
Moura et al. The close interplay of nitro-oxidative stress, advanced glycation end products and inflammation in inflammatory bowel diseases
Cao et al. Effects of L-carnitine on high glucose-induced oxidative stress in retinal ganglion cells
Pasquali-Ronchetti et al. Pseudoxanthoma elasticum: biochemical and ultrastructural studies
Peluso et al. Carnitine protects the molecular chaperone activity of lens α‐crystallin and decreases the posttranslational protein modifications induced by oxidative stress
US20100210531A1 (en) Agents with angiogenic and wound healing activity
SK287787B6 (sk) Použitie L-karnitínu ako stabilizačného činidla proteínov
Ghosh et al. Crowded milieu prevents fibrillation of hen egg white lysozyme with retention of enzymatic activity
Castino et al. Autophagy is a prosurvival mechanism in cells expressing an autosomal dominant familial neurohypophyseal diabetes insipidus mutant vasopressin transgene
Ringvold A preliminary report on the amino acid composition of the pseudo-exfoliation material (PE material)
Shun-Shin et al. Morphologic characteristics and chemical composition of Christmas tree cataract.
RU2627769C1 (ru) 9-Бензил-2-бифенилимидазо[1,2-а]бензимидазол и его фармацевтически приемлемые соли, проявляющие свойства разрушителей поперечных сшивок гликированных белков
Raju et al. Role of αA-crystallin-derived αA66-80 peptide in guinea pig lens crystallin aggregation and insolubilization
EP3156064B1 (en) Application of yb-1 protein and fragments thereof for preparing medicinal agents in treating alzheimer's disease
CZ20031891A3 (cs) Použití L-karnitinu jako stabilizátoru proteinů
WO2006132205A1 (ja) ラジカルスカベンジャー及び活性酸素消去剤
BRPI0706883A2 (pt) composto de sal de azaciclo de 5 membros substituìdo, composição farmacêutica, método para preparar um composto e uso de um composto
Williams Studies on azide, caeruloplasmin and copper in relation to Wilson's disease.
RU2797514C1 (ru) Фармакологическая субстанция мембранотропных гомеостатических тканеспецифических биорегуляторов, выделенных из различных тканей и биологических жидкостей животных
RU2727159C1 (ru) Композиция полипептидов, обладающая свойством нормализовать функции головного мозга
EP0610481A1 (en) Extraction of collagen

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20161215